CN115340615B - Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof - Google Patents
Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof Download PDFInfo
- Publication number
- CN115340615B CN115340615B CN202210966480.1A CN202210966480A CN115340615B CN 115340615 B CN115340615 B CN 115340615B CN 202210966480 A CN202210966480 A CN 202210966480A CN 115340615 B CN115340615 B CN 115340615B
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- amino acid
- fluorescent
- aureomycin
- aldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010189 synthetic method Methods 0.000 title description 3
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229960004475 chlortetracycline Drugs 0.000 claims abstract description 53
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims abstract description 53
- 235000019365 chlortetracycline Nutrition 0.000 claims abstract description 53
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 20
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 10
- 229960004853 betadex Drugs 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract 9
- 230000001590 oxidative effect Effects 0.000 claims abstract 2
- 229940024606 amino acid Drugs 0.000 claims description 55
- 239000000243 solution Substances 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- 229960002885 histidine Drugs 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 230000005284 excitation Effects 0.000 claims description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 229960002449 glycine Drugs 0.000 claims description 8
- 235000008729 phenylalanine Nutrition 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 229960005190 phenylalanine Drugs 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000009697 arginine Nutrition 0.000 claims description 7
- 229960003121 arginine Drugs 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 229960002433 cysteine Drugs 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 229960002989 glutamic acid Drugs 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- 235000004554 glutamine Nutrition 0.000 claims description 7
- 229960002743 glutamine Drugs 0.000 claims description 7
- 235000014705 isoleucine Nutrition 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 235000018977 lysine Nutrition 0.000 claims description 7
- 229960003646 lysine Drugs 0.000 claims description 7
- 235000006109 methionine Nutrition 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000012086 standard solution Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000001728 nano-filtration Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 3
- 229960004799 tryptophan Drugs 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 230000000007 visual effect Effects 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 description 13
- 239000004099 Chlortetracycline Substances 0.000 description 8
- 239000004098 Tetracycline Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004100 Oxytetracycline Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004023 minocycline Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960000625 oxytetracycline Drugs 0.000 description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 3
- 235000019366 oxytetracycline Nutrition 0.000 description 3
- 231100000719 pollutant Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 3
- 229940072172 tetracycline antibiotic Drugs 0.000 description 3
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical group N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011540 sensing material Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- JXBAVRIYDKLCOE-UHFFFAOYSA-N [C].[P] Chemical class [C].[P] JXBAVRIYDKLCOE-UHFFFAOYSA-N 0.000 description 1
- YUWBVKYVJWNVLE-UHFFFAOYSA-N [N].[P] Chemical compound [N].[P] YUWBVKYVJWNVLE-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007833 carbon precursor Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- -1 sodium alginate Chemical class 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N21/643—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" non-biological material
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/14—Macromolecular compounds
- C09K2211/1441—Heterocyclic
- C09K2211/145—Heterocyclic containing oxygen as the only heteroatom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
技术领域technical field
本发明属于荧光传感器技术领域,涉及一种基于环糊精-氨基酸的荧光分子及其合成方法与在金霉素荧光检测中的应用。The invention belongs to the technical field of fluorescence sensors, and relates to a cyclodextrin-amino acid-based fluorescent molecule, a synthesis method thereof and an application in aureomycin fluorescence detection.
背景技术Background technique
有机荧光材料已广泛应用于传感器、细胞成像和显示技术。传统荧光分子均具有基于π-共轭芳香结构的化学键共轭的结构基础,具有可调的发光颜色和高荧光效率。然而,这些材料通常具有溶解性差、生物毒性高、成本高、合成工艺复杂等特点,极大地限制了其实际应用。相比之下,没有显著共轭结构的非常规发光体具有高生物相容性、低毒性、良好的可加工性和易于合成的独特优势。非常规发光体具有富电子的杂原子,例如氮(N)、氧(O)、硫(S)、磷(P)、卤素(Cl、Br和I)或含有C=O、C=C和C≡N的不饱和基团。它们在浓溶液和/或固态中发射,但在稀溶液中往往不发光。这种现象被称为团簇触发发射(CTE)。聚集状态的簇发光体已被用于加密和生物成像。然而,用于细胞成像的簇发光体的浓度比传统发光体高1000倍,这成为其实际应用的一大障碍。此外,在传感应用中,荧光探针需要与分析物进行有效的相互作用。然而,目前基于簇集发光的固态的团簇发光材料和水溶液中的分析物之间的相互作用有限,所报道的非常规发光体作为传感器的性能较差。因此,非常需要寻找新的策略来促进即使在稀溶液中也具有强发光的CTE效应。Organic fluorescent materials have been widely used in sensors, cell imaging and display technologies. Traditional fluorescent molecules all have the structural basis of chemical bond conjugation based on π-conjugated aromatic structures, which have tunable emission colors and high fluorescence efficiency. However, these materials usually have the characteristics of poor solubility, high biological toxicity, high cost, and complicated synthesis process, which greatly limit their practical application. In contrast, unconventional luminophores without significant conjugated structures have unique advantages of high biocompatibility, low toxicity, good processability, and easy synthesis. Unconventional emitters have electron-rich heteroatoms such as nitrogen (N), oxygen (O), sulfur (S), phosphorus (P), halogens (Cl, Br and I) or contain C=O, C=C and C≡N unsaturated group. They emit in concentrated solutions and/or in the solid state, but tend not to emit light in dilute solutions. This phenomenon is known as cluster triggered emission (CTE). Cluster luminophores in the aggregated state have been used for encryption and bioimaging. However, the concentration of cluster luminophores for cell imaging is 1000 times higher than that of conventional luminophores, which becomes a major obstacle for their practical applications. Furthermore, fluorescent probes need to interact efficiently with analytes for sensing applications. However, current cluster-based solid-state cluster luminescent materials have limited interactions with analytes in aqueous solution, and the reported unconventional luminophores have poor performance as sensors. Therefore, it is highly desirable to find new strategies to promote CTE effects with strong luminescence even in dilute solutions.
具有丰富羟基的单-、双-、寡-和多糖结晶作为非常规发光体的发光现象已被广泛研究。它们在稀溶液中是弱发射的,并且仅从浓溶液(>8wt.%)或结晶状态观察到明亮的发射。在稀溶液中,线性多糖,例如海藻酸钠,显示出延伸的蠕虫状构象,这导致由于缺乏足够的电子离域和活跃的分子运动而不发光。因此,开发非线性分子和增强分子堆积对于在稀溶液中获得明亮的发光具有重要意义。Mono-, bis-, oligo-, and polysaccharide crystals with abundant hydroxyl groups have been extensively studied as unconventional emitters. They are weakly emissive in dilute solutions, and bright emission is only observed from concentrated solutions (>8 wt.%) or crystalline state. In dilute solutions, linear polysaccharides, such as sodium alginate, display extended worm-like conformations, which lead to non-luminescence due to lack of sufficient electron delocalization and active molecular motion. Therefore, developing nonlinear molecules and enhancing molecular packing are of great significance for obtaining bright luminescence in dilute solutions.
相比于传统的检测方法,荧光探针技术由于具有简单便携、高灵敏度、成本低等特点,被认为是检测痕量污染物的最有前景的分析方法之一。目前,四环素作为水体中经常被检出的新型污染物,已经报道了多种荧光传感材料用于检测四环素类抗生素。然而,对于分子主体结构十分相似的四环素抗生素如金霉素、土霉素、美诺环素、四环素等,很难区分。因此,需要设计针对某一特定四环素类抗生素的荧光探针进行开发与应用。Compared with traditional detection methods, fluorescent probe technology is considered to be one of the most promising analytical methods for detecting trace pollutants due to its simplicity, portability, high sensitivity, and low cost. At present, tetracycline is a new type of pollutant that is often detected in water, and a variety of fluorescent sensing materials have been reported for the detection of tetracycline antibiotics. However, it is difficult to distinguish tetracycline antibiotics such as chlortetracycline, oxytetracycline, minocycline, tetracycline, etc., whose main molecular structure is very similar. Therefore, it is necessary to design a fluorescent probe for a specific tetracycline antibiotic for development and application.
目前基于环糊精-氨基酸的新型荧光分子尚未报道。已报道的技术比如中国专利CN 201810866243.1公开了一种安全简单制备双掺杂氮和磷碳量子点的方法,该方法先将氨基酸、碳前驱体(包括葡萄糖、一水合柠檬酸或环糊精)溶解在去离子水中,加入磷酸溶液,后经超声波处理1~2h;将超声过后的溶液在90-150℃下油浴加热1-5小时,制备出氮、磷共掺杂碳点溶液。通过专利对比,该专利中虽然也采用了氨基酸、环糊精等原料,但制备方法和最终产物明显不同,该专利采用超声、高温油浴等方法得到的氮和磷双掺杂碳量子点,合成时间较长,处理过程复杂。相对而言,本发明中基于氨基酸接枝环糊精的新型荧光分子,与碳量子点不同,具有明确的分子组成和空间结构,合成条件温和,合成温度为60-80℃,反应时间仅为30-60min。此外,以组氨酸接枝环糊精的荧光分子可作为金霉素的特异性识别探针,可实现对金霉素的高灵敏度、高选择性的便携式检测,显示了良好的应用前景。No new fluorescent molecules based on cyclodextrin-amino acids have been reported yet. Reported technologies such as Chinese patent CN 201810866243.1 disclose a safe and simple method for preparing double-doped nitrogen and phosphorus-carbon quantum dots. In this method, amino acids and carbon precursors (including glucose, citric acid monohydrate or cyclodextrin) Dissolve in deionized water, add phosphoric acid solution, and then undergo ultrasonic treatment for 1-2 hours; heat the sonicated solution in an oil bath at 90-150°C for 1-5 hours to prepare a nitrogen-phosphorus co-doped carbon dot solution. Through patent comparison, although amino acids, cyclodextrin and other raw materials are also used in this patent, the preparation method is obviously different from the final product. The patent uses nitrogen and phosphorus double-doped carbon quantum dots obtained by ultrasonic, high-temperature oil bath, etc. The synthesis time is long and the processing process is complicated. Relatively speaking, the new fluorescent molecule based on amino acid grafted cyclodextrin in the present invention, unlike carbon quantum dots, has a clear molecular composition and spatial structure, the synthesis conditions are mild, the synthesis temperature is 60-80°C, and the reaction time is only 30-60min. In addition, the fluorescent molecule grafted with histidine cyclodextrin can be used as a specific recognition probe of aureomycin, which can realize the portable detection of aureomycin with high sensitivity and high selectivity, showing a good application prospect.
在金霉素的荧光分析技术方面,已报道的技术比如中国专利CN201710302455.2公开了一种基于聚乙烯亚胺保护的金/铂双金属纳米簇荧光探针及其在检测金霉素中的应用,该方法利用聚乙烯亚胺保护的双金属金/铂纳米簇作为荧光传感材料,基于荧光猝灭的机制用于检测四环素类抗生素;然而,仍需通过加入Al3+基于荧光增强的机制,才可将金霉素从四环素中区分开,达到特异性检测金霉素的目的。其对金霉素进行检测,线性范围为0.5-30μM,检测限为0.5μM。但该检测方法的检测限仍旧较高,难以满足现有污水中微量金霉素的检测要求。In terms of fluorescence analysis technology of aureomycin, reported technologies such as Chinese patent CN201710302455.2 disclose a gold/platinum bimetallic nanocluster fluorescent probe based on polyethyleneimine protection and its application in the detection of aureomycin. application, this method uses polyethylenimine-protected bimetallic gold/platinum nanoclusters as a fluorescent sensing material based on the mechanism of fluorescence quenching for the detection of tetracycline antibiotics; Mechanism, aureomycin can be distinguished from tetracycline, to achieve the purpose of specific detection of aureomycin. It detects aureomycin with a linear range of 0.5-30 μM and a detection limit of 0.5 μM. However, the detection limit of this detection method is still high, and it is difficult to meet the detection requirements of trace aureomycin in existing sewage.
发明内容Contents of the invention
本发明的目的就是提供一种基于环糊精-氨基酸的荧光分子及其合成方法与应用。The object of the present invention is to provide a fluorescent molecule based on cyclodextrin-amino acid and its synthesis method and application.
本发明的目的可以通过以下技术方案来实现:The purpose of the present invention can be achieved through the following technical solutions:
一种基于环糊精-氨基酸的荧光分子合成方法,包括:A method for synthesizing fluorescent molecules based on cyclodextrin-amino acids, comprising:
将醛基环糊精、氨基酸加入至水中配制成混合液,并依次经过调节pH、加热搅拌、固液分离后,即得到基于环糊精-氨基酸的荧光分子;其中所述的醛基环糊精为采用高碘酸钠预氧化β-环糊精得到的醛基环糊精。Add aldehyde cyclodextrin and amino acid to water to prepare a mixed solution, and after adjusting pH, heating and stirring, and solid-liquid separation in sequence, the fluorescent molecule based on cyclodextrin-amino acid is obtained; the aldehyde cyclodextrin The essence is aldehyde cyclodextrin obtained by preoxidizing β-cyclodextrin with sodium periodate.
进一步地,所述的醛基环糊精的制备方法包括:Further, the preparation method of described aldehyde cyclodextrin comprises:
将β-环糊精与高碘酸钠于水中避光搅拌反应,经纳滤后,与乙醇搅拌混合至沉淀析出,之后依次经过滤、洗涤、冻干后,得到醛基环糊精;β-cyclodextrin and sodium periodate are stirred and reacted in water in the dark, and after nanofiltration, they are stirred and mixed with ethanol until precipitation occurs, followed by filtration, washing, and freeze-drying to obtain aldehyde cyclodextrin;
其中,所述的β-环糊精与高碘酸钠的摩尔比为1:(1-4);Wherein, the mol ratio of described β-cyclodextrin and sodium periodate is 1:(1-4);
所述的避光搅拌反应中,反应温度为30-50℃,反应时间为3-5h;In the said dark stirring reaction, the reaction temperature is 30-50°C, and the reaction time is 3-5h;
纯化过程中采用体积比1/4的水/乙醇混合溶液进行洗涤。During the purification process, a water/ethanol mixed solution with a volume ratio of 1/4 was used for washing.
进一步地,所述的醛基环糊精、氨基酸的摩尔比为1:(2-6)。Further, the molar ratio of the aldehyde cyclodextrin to amino acid is 1:(2-6).
进一步地,所述的氨基酸包括甘氨酸、异亮氨酸、甲硫氨酸、半胱氨酸,谷氨酸、谷氨酰胺、天冬酰胺、精氨酸、赖氨酸、苯丙氨酸、色氨酸或组氨酸中的至少一种。Further, the amino acids include glycine, isoleucine, methionine, cysteine, glutamic acid, glutamine, asparagine, arginine, lysine, phenylalanine, At least one of tryptophan or histidine.
进一步地,当氨基酸为甘氨酸、异亮氨酸、甲硫氨酸、半胱氨酸,谷氨酸、谷氨酰胺、天冬酰胺、精氨酸、赖氨酸或苯丙氨酸中的至少一种时,调节反应体系pH至8-9;Further, when the amino acid is at least one of glycine, isoleucine, methionine, cysteine, glutamic acid, glutamine, asparagine, arginine, lysine or phenylalanine One time, adjust the pH of the reaction system to 8-9;
当氨基酸为色氨酸或组氨酸中的一种或两种时,调节反应体系pH至6-7。When the amino acid is one or both of tryptophan or histidine, adjust the pH of the reaction system to 6-7.
进一步地,加热搅拌过程中,加热温度为60-80℃,搅拌时间为30-60min。Further, during the heating and stirring process, the heating temperature is 60-80° C., and the stirring time is 30-60 min.
进一步地,所述的固液分离包括透析与冷冻干燥。Further, the solid-liquid separation includes dialysis and freeze-drying.
一种基于环糊精-氨基酸的荧光分子,采用如上所述的方法合成。A fluorescent molecule based on cyclodextrin-amino acid is synthesized by the above-mentioned method.
一种基于环糊精-氨基酸的荧光分子的应用,包括将所述的荧光分子作为荧光探针,用于水体中金霉素的定性和/或定量检测。The application of a cyclodextrin-amino acid-based fluorescent molecule includes using the fluorescent molecule as a fluorescent probe for qualitative and/or quantitative detection of aureomycin in water.
进一步地,检测方法具体包括以下步骤:Further, the detection method specifically includes the following steps:
1)绘制标准曲线:将荧光探针分别与多个含不同浓度金霉素的溶液混合并搅拌均匀,得到金霉素浓度范围为0-5μM的标准溶液,利用365nm紫外灯作为激发光源,在黑暗环境下拍摄获得荧光图像,并分析图像B值与G值,以B/G为纵坐标,以金霉素浓度为横坐标绘制标准曲线,以及金霉素检测拟合方程;1) Draw a standard curve: Mix the fluorescent probe with a plurality of solutions containing different concentrations of chlortetracycline and stir evenly to obtain a standard solution with a concentration of chlortetracycline in the range of 0-5 μM. Use a 365nm ultraviolet lamp as an excitation light source. Take the fluorescent image in a dark environment, and analyze the B value and G value of the image, take B/G as the vertical axis, and take the aureomycin concentration as the abscissa to draw the standard curve, and the aureomycin detection fitting equation;
2)水样中金霉素的检测:采用同步骤1)中荧光探针与金霉素的溶液的用量比,将荧光探针与待测水样混合,得到混合样,以365nm紫外灯为激发光源获得荧光图像,并分析计算得到图像的B/G,之后根据标准曲线或拟合方程,得到对应的金霉素浓度。2) Detection of aureomycin in the water sample: adopt the same step 1) in the amount ratio of the fluorescent probe and the solution of aureomycin, mix the fluorescent probe with the water sample to be tested to obtain a mixed sample, use a 365nm ultraviolet lamp as the Excite the light source to obtain the fluorescence image, analyze and calculate the B/G of the image, and then obtain the corresponding aureomycin concentration according to the standard curve or fitting equation.
本发明首先利用高碘酸钠对溶解性低和反应活性低的β-环糊精进行氧化改性,得到水溶性好且反应活性高并含有双醛结构的醛基环糊精;然后通过醛基环糊精的醛基与各类氨基酸分子中的氨基通过席夫碱反应,得到基于不同种类氨基酸的12种氨基酸接枝环糊精的新型荧光分子。所合成的荧光分子基于增强簇集发光的机理,具有在稀溶液中优良的荧光性能,具有良好的水溶性和优异的环境相容性。合成的组氨酸接枝环糊精的荧光分子作为金霉素的荧光探针,可实现对金霉素的高选择性和高灵敏度的基于可视化技术的便携式检测。The present invention first uses sodium periodate to oxidize and modify β-cyclodextrin with low solubility and low reactivity to obtain aldehyde-based cyclodextrin with good water solubility, high reactivity and dialdehyde structure; The aldehyde group of the base cyclodextrin reacts with the amino group in various amino acid molecules through Schiff base reaction to obtain a new type of fluorescent molecule based on 12 kinds of amino acids grafted with cyclodextrin of different types of amino acids. The synthesized fluorescent molecules are based on the mechanism of enhanced cluster luminescence, have excellent fluorescent properties in dilute solutions, have good water solubility and excellent environmental compatibility. The synthetic histidine-grafted cyclodextrin fluorescent molecule is used as a fluorescent probe of aureomycin, which can realize a portable detection of aureomycin with high selectivity and high sensitivity based on visualization technology.
与现有技术相比,本发明具有以下特点:Compared with the prior art, the present invention has the following characteristics:
1)本发明的合成方法简单,通过对环糊精简单改性后得到,并且合成条件较为温和,反应温度可控制在80℃以下,基于常规的水浴条件即可提供制备环境要求;1) The synthesis method of the present invention is simple, obtained by simple modification of cyclodextrin, and the synthesis conditions are relatively mild, the reaction temperature can be controlled below 80°C, and the preparation environment requirements can be provided based on conventional water bath conditions;
2)本发明制备得到的环糊精-氨基酸的新型荧光分子与传统具有共轭结构的荧光分子相比,具备结构简单、合成成本低、水溶性好、无生物毒性、环境相容性好等优点。2) Compared with traditional fluorescent molecules with conjugated structures, the novel fluorescent molecules of cyclodextrin-amino acids prepared by the present invention have simple structures, low synthesis costs, good water solubility, no biological toxicity, and good environmental compatibility, etc. advantage.
3)本发明可合成一系列具有丰富结构和性能的环糊精-氨基酸新型荧光分子,提供了合成基于氨基酸-环糊精的非常规荧光材料的通用方法。3) The present invention can synthesize a series of cyclodextrin-amino acid novel fluorescent molecules with rich structures and properties, and provides a general method for synthesizing unconventional fluorescent materials based on amino acid-cyclodextrin.
4)本发明制备得到的环糊精-组氨酸的新型荧光分子,可直接高特性识别金霉素分子,实现对金霉素的高灵敏性检测(检测范围为0-5μM,检测限为12nM),更适合低浓度的微量污染物的精准检测,以及高选择性检测,而其对于分子主体结构十分相似的其他类四环素无信号响应,此外通过基于荧光图像的可视化技术可实现对金霉素的便携式检测。4) The novel fluorescent molecule of cyclodextrin-histidine prepared by the present invention can directly identify the chlortetracycline molecule with high characteristics, and realize the highly sensitive detection of chlortetracycline (the detection range is 0-5 μ M, and the detection limit is 12nM), which is more suitable for the precise detection of low-concentration trace pollutants and high selectivity detection, but it has no signal response to other tetracyclines with very similar molecular main structures. A portable assay for phenotypes.
附图说明Description of drawings
图1为实施例1与实施例2中合成的环糊精-氨基酸的荧光分子的三维荧光图;Fig. 1 is the three-dimensional fluorescence diagram of the fluorescent molecule of cyclodextrin-amino acid synthesized in
图2为实施例1与实施例2中合成的环糊精-氨基酸的荧光分子的在不同激发波长条件下的发射光谱图;Fig. 2 is the emission spectrogram of the cyclodextrin-amino acid fluorescent molecule synthesized in Example 1 and Example 2 under different excitation wavelength conditions;
图3为实施例3中不同氨基酸添加量的条件下环糊精-组氨酸的荧光光谱;Fig. 3 is the fluorescence spectrum of cyclodextrin-histidine under the condition of different amino acid addition amount in
图4为实施例4中加入不同浓度的金霉素后的荧光发射光谱;Fig. 4 is the fluorescence emission spectrum after adding the aureomycin of different concentrations in
图5为实施例4中所绘制的金霉素检测标准曲线;Fig. 5 is the aureomycin detection standard curve drawn in
图6为实施例5中不同的有机小分子对合成的环糊精-组氨酸荧光分子的荧光发射光谱的影响。Fig. 6 is the effect of different organic small molecules on the fluorescence emission spectrum of the synthesized cyclodextrin-histidine fluorescent molecule in Example 5.
具体实施方式Detailed ways
下面结合附图和具体实施例对本发明进行详细说明。The present invention will be described in detail below in conjunction with the accompanying drawings and specific embodiments.
一种基于环糊精-氨基酸的荧光分子,其合成方法包括以下步骤:A kind of fluorescent molecule based on cyclodextrin-amino acid, its synthesis method comprises the following steps:
S1:将β-环糊精与高碘酸钠以摩尔比为1:(1-4)于水中混合,并在30-50℃下避光搅拌反应3-5h,经纳滤后,与乙醇搅拌混合至沉淀析出,之后依次经过滤、纯化、冻干,得到醛基环糊精;S1: Mix β-cyclodextrin and sodium periodate in water at a molar ratio of 1:(1-4), and stir for 3-5 hours at 30-50°C in the dark, then filter with ethanol Stir and mix until the precipitate is separated out, then filter, purify, and freeze-dry in sequence to obtain aldehyde cyclodextrin;
其中,纯化过程为采用体积比1/4的水/乙醇混合溶液进行洗涤;Wherein, the purification process is to use a water/ethanol mixed solution with a volume ratio of 1/4 for washing;
S2:将醛基环糊精配制成水溶液;S2: preparing aldehyde cyclodextrin into an aqueous solution;
S3:将氨基酸加入至上述水溶液中,调节体系的pH值,并加热至60-80℃,持续搅拌30-60min,得到产品液;S3: adding amino acid to the above aqueous solution, adjusting the pH value of the system, heating to 60-80°C, and continuously stirring for 30-60min to obtain the product liquid;
其中,醛基环糊精、氨基酸的摩尔比为1:(2-6);Wherein, the mol ratio of aldehyde cyclodextrin and amino acid is 1:(2-6);
当氨基酸为甘氨酸、异亮氨酸、甲硫氨酸、半胱氨酸,谷氨酸、谷氨酰胺、天冬酰胺、精氨酸、赖氨酸或苯丙氨酸中的至少一种时,调节反应体系pH至8-9;When the amino acid is at least one of glycine, isoleucine, methionine, cysteine, glutamic acid, glutamine, asparagine, arginine, lysine, or phenylalanine , adjust the pH of the reaction system to 8-9;
当氨基酸为色氨酸或组氨酸中的一种或两种时,调节反应体系pH至6-7;When the amino acid is one or both of tryptophan or histidine, adjust the pH of the reaction system to 6-7;
S4:将产品液进行透析12h,得到的透析液进行冷冻干燥,即可得到基于环糊精-氨基酸的新型荧光材料粉末。S4: The product solution is dialyzed for 12 hours, and the obtained dialysate is freeze-dried to obtain a novel fluorescent material powder based on cyclodextrin-amino acid.
一种基于环糊精-氨基酸的荧光分子的应用,包括将所述的荧光分子作为荧光探针,用于水体中金霉素的定性和/或定量检测。The application of a cyclodextrin-amino acid-based fluorescent molecule includes using the fluorescent molecule as a fluorescent probe for qualitative and/or quantitative detection of aureomycin in water.
进一步地,检测方法具体包括以下步骤:Further, the detection method specifically includes the following steps:
1)绘制标准曲线:将荧光探针分别与多个含不同浓度金霉素的溶液混合并搅拌均匀,得到金霉素浓度范围为0-5μM的标准溶液,利用365nm紫外灯作为激发光源,在黑暗环境下拍摄获得荧光图像,利用软件image J进行图像颜色均一化处理,然后利用F取色器直接读取图像的平均B值与G值,以B/G为纵坐标,以金霉素浓度为横坐标绘制标准曲线,以及金霉素检测拟合方程;1) Draw a standard curve: Mix the fluorescent probe with a plurality of solutions containing different concentrations of chlortetracycline and stir evenly to obtain a standard solution with a concentration of chlortetracycline in the range of 0-5 μM. Use a 365nm ultraviolet lamp as an excitation light source. Fluorescent images were captured in a dark environment, and the image color was uniformized using the software image J, and then the average B value and G value of the image were directly read using the F color picker, with B/G as the ordinate, and the concentration of aureomycin Draw a standard curve for the abscissa, and a chlortetracycline detection fitting equation;
2)水样中金霉素的检测:采用同步骤1)中荧光探针与金霉素的溶液的用量比,将荧光探针与待测水样混合,得到混合样,以365nm紫外灯为激发光源获得荧光图像,并分析计算得到图像的B/G,之后根据标准曲线或拟合方程,得到对应的金霉素浓度。2) Detection of aureomycin in the water sample: adopt the same step 1) in the amount ratio of the fluorescent probe and the solution of aureomycin, mix the fluorescent probe with the water sample to be tested to obtain a mixed sample, use a 365nm ultraviolet lamp as the Excite the light source to obtain the fluorescence image, analyze and calculate the B/G of the image, and then obtain the corresponding aureomycin concentration according to the standard curve or fitting equation.
本实施例以本发明技术方案为前提进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。This embodiment is carried out on the premise of the technical solution of the present invention, and detailed implementation and specific operation process are given, but the protection scope of the present invention is not limited to the following embodiments.
实施例1:Example 1:
一种基于环糊精-氨基酸(组氨酸/色氨酸)的荧光分子,其合成方法包括以下步骤:A fluorescent molecule based on cyclodextrin-amino acid (histidine/tryptophan), its synthesis method comprises the following steps:
S1:将15gβ-环糊精加入至100mL去离子水中,并搅拌均匀,再加入6g高碘酸钠,并在40℃下避光搅拌反应4h,经220nm滤膜过滤后,取滤出液并与过量无水乙醇(800mL)混合至沉淀析出,之后依次经过滤、乙醇/水(V/V=80/20)多次洗涤、冷冻干燥,得到水溶性好且反应活性高并含有双醛结构的醛基环糊精;S1: Add 15g of β-cyclodextrin to 100mL of deionized water, and stir evenly, then add 6g of sodium periodate, and stir for 4 hours at 40°C in the dark, filter through a 220nm filter membrane, take the filtrate and Mix it with excess absolute ethanol (800mL) until it precipitates out, then filter, wash with ethanol/water (V/V=80/20) multiple times, and freeze-dry to obtain a dialdehyde structure with good water solubility and high reactivity. Aldehyde cyclodextrin;
S2:将0.1mmol(114mg)醛基环糊精与0.6mmol(93mg)组氨酸或0.6mmol(82mg)色氨酸共溶于20mL水中,调节体系pH为6-7;S2: Dissolve 0.1mmol (114mg) aldehyde cyclodextrin and 0.6mmol (93mg) histidine or 0.6mmol (82mg) tryptophan in 20mL water to adjust the pH of the system to 6-7;
S3:将上述溶液在80℃下搅拌反应60min,得到环糊精-氨基酸荧光分子,经过透析(截留分子量1000Da),冷冻干燥后分别得到2种基于环糊精-氨基酸(组氨酸/色氨酸)的荧光材料粉末。S3: The above solution was stirred and reacted at 80°C for 60 minutes to obtain cyclodextrin-amino acid fluorescent molecules, which were dialyzed (molecular weight cut-off 1000Da) and freeze-dried to obtain two cyclodextrin-amino acid (histidine/tryptophan) molecules. Acid) fluorescent material powder.
实施例2:Example 2:
一种基于环糊精-氨基酸(甘氨酸、异亮氨酸、甲硫氨酸、半胱氨酸,谷氨酸、谷氨酰胺、天冬酰胺、精氨酸、赖氨酸或苯丙氨酸)的荧光分子,其合成方法与实施例1相比区别仅在于:A cyclodextrin-based amino acid (glycine, isoleucine, methionine, cysteine, glutamic acid, glutamine, asparagine, arginine, lysine or phenylalanine ) fluorescent molecule, its synthetic method compared with
步骤S2中,所用氨基酸为0.6mmol(45mg)甘氨酸或0.6mmol(79mg)异亮氨酸、0.6mmol(105mg)精氨酸、0.6mmol(79mg)天冬酰胺、0.6mmol(73mg)半胱氨酸、0.6mmol(88mg)谷氨酰胺、0.6mmol(88mg)谷氨酸、0.6mmol(88mg)赖氨酸、0.6mmol(90mg)甲硫氨酸、0.6mmol(99mg)苯丙氨酸;调解体系pH至8-9;In step S2, the amino acid used is 0.6mmol (45mg) glycine or 0.6mmol (79mg) isoleucine, 0.6mmol (105mg) arginine, 0.6mmol (79mg) asparagine, 0.6mmol (73mg) cysteine acid, 0.6mmol (88mg) glutamine, 0.6mmol (88mg) glutamic acid, 0.6mmol (88mg) lysine, 0.6mmol (90mg) methionine, 0.6mmol (99mg) phenylalanine; mediation System pH to 8-9;
步骤S3中,搅拌反应时间为30min,最终得到10种基于环糊精-氨基酸的荧光材料粉末;In step S3, the stirring reaction time is 30 minutes, and finally 10 kinds of fluorescent material powders based on cyclodextrin-amino acid are obtained;
其余同实施例1。All the other are with
如图1所示,为实施例1与实施例2所合成的12种基于环糊精-氨基酸的新型荧光分子(5mM水溶液)的三维荧光。从图中可以看出,基于在环糊精受限的空间内的增强簇集发光效应,合成的环糊精-氨基酸新型荧光分子虽然不具有π-共轭基团,但仍具有明显的荧光信号,发射波长集中在350-550nm范围内。As shown in FIG. 1 , it is the three-dimensional fluorescence of 12 novel fluorescent molecules (5 mM aqueous solution) based on cyclodextrin-amino acid synthesized in Example 1 and Example 2. It can be seen from the figure that based on the enhanced cluster luminescence effect in the cyclodextrin-confined space, the synthesized cyclodextrin-amino acid novel fluorescent molecule does not have π-conjugated groups, but still has obvious fluorescence Signal, the emission wavelength is concentrated in the range of 350-550nm.
如图2所示,为所合成的12种基于环糊精-氨基酸的新型荧光分子(5mM水溶液)在不同激发波长下的发射光谱。从图中可以看出,合成的新型荧光分子具有激发波长依赖性,随着激发波长增大,发射峰逐渐红移。As shown in FIG. 2 , it is the emission spectra of the synthesized 12 cyclodextrin-amino acid-based novel fluorescent molecules (5 mM aqueous solution) at different excitation wavelengths. It can be seen from the figure that the new fluorescent molecules synthesized have excitation wavelength dependence, and the emission peak gradually red shifts as the excitation wavelength increases.
实施例3:不同氨基酸添加量的影响Embodiment 3: the impact of different amino acid additions
一种基于环糊精-氨基酸(组氨酸)的荧光分子,其合成方法与实施例1相比区别仅在于:A fluorescent molecule based on cyclodextrin-amino acid (histidine), its synthetic method compared with Example 1 only differs in that:
步骤S2中,所用组氨酸用量分别为31mg,62mg,93mg,124mg(醛基环糊精、氨基酸的摩尔比分别为1:2,1:4,1:6,1:8);其余同实施例1。In step S2, the amount of histidine used is 31mg, 62mg, 93mg, 124mg respectively (the molar ratios of aldehyde cyclodextrin and amino acid are 1:2, 1:4, 1:6, 1:8 respectively); the rest are the same Example 1.
以365nm紫外灯作为激发光源,测量浓度为5mM(水溶液)时的荧光发射曲线,结果如图3所示,随着组氨酸添加量的增加,荧光强度逐渐增加。当添加摩尔比例为1:8,荧光强度增加不明显。Using a 365nm ultraviolet lamp as the excitation light source, the fluorescence emission curve was measured at a concentration of 5mM (aqueous solution). The results are shown in Figure 3. As the amount of histidine added increases, the fluorescence intensity gradually increases. When the added molar ratio is 1:8, the fluorescence intensity does not increase significantly.
实施例4:Example 4:
本实施例以实施例1所制备的基于环糊精-组氨酸的荧光分子作为荧光探针,用于检测水样中的金霉素,具体检测过程如下:In this example, the cyclodextrin-histidine-based fluorescent molecule prepared in Example 1 is used as a fluorescent probe for detecting aureomycin in water samples. The specific detection process is as follows:
1)绘制标准曲线:将基于环糊精-氨基酸荧光分子分散至去离子水中,浓度为200μM,用作荧光探针;1) Draw a standard curve: disperse cyclodextrin-amino acid-based fluorescent molecules into deionized water at a concentration of 200 μM, and use them as fluorescent probes;
分别配制浓度为0、1、2、4、6、8、10μM的金霉素标准溶液,并各取0.5mL与等体积的荧光探针混合,得到混合液,在黑暗环境下利用365nm紫外灯作为激发光源,测量所得混合液的荧光发射曲线,结果如图4所示,从图中可以看出,随着加入金霉素的浓度增大,体系的荧光强度逐渐增强;Prepare achlortetracycline standard solutions with concentrations of 0, 1, 2, 4, 6, 8, and 10 μM respectively, and mix 0.5 mL each with an equal volume of fluorescent probe to obtain a mixed solution, and use a 365 nm ultraviolet lamp in a dark environment to As an excitation light source, the fluorescence emission curve of the obtained mixed solution was measured, and the results are shown in Figure 4. It can be seen from the figure that as the concentration of aureomycin added increases, the fluorescence intensity of the system gradually increases;
对上述混合液进行拍照获得荧光图像,随着金霉素浓度增大,图像亮度逐渐增大,利用图像分析软件分析图像的B值与G值,以B/G为纵坐标,以金霉素浓度(μM)为横坐标绘制标准曲线(如图5所示),并得到金霉素检测拟合方程:y=0.1431x+1.3319,(R2=0.998);根据检出限LOD=3σ/N(其中,σ为空白样品的标准偏差,N为线性方程的斜率)计算得出,以环糊精-组氨酸的荧光分子为探针的检出限为12nM。The above mixed solution was photographed to obtain a fluorescence image. As the concentration of aureomycin increased, the brightness of the image gradually increased. Use image analysis software to analyze the B value and G value of the image, with B/G as the ordinate, and Aureomycin as the ordinate. Concentration (μ M) draws standard curve (as shown in Figure 5) for abscissa, and obtains aureomycin detection fitting equation: y=0.1431x+1.3319, (R2=0.998); According to limit of detection LOD=3σ/N (wherein, σ is the standard deviation of the blank sample, and N is the slope of the linear equation). It is calculated that the detection limit of the probe is 12nM using the fluorescent molecule of cyclodextrin-histidine.
2)待测水样预处理:将待测水样过滤,调节其pH为中性;2) Pretreatment of the water sample to be tested: filter the water sample to be tested and adjust its pH to be neutral;
3)水样中金霉素的检测:取0.5mL预处理水样,与0.5mL荧光探针溶液混合,得到混合样,以365nm紫外灯为激发光源获得荧光图像后并使用图像分析软件得到图像的B/G,之后根据拟合方程,得到对应的金霉素浓度。采集同济大学(四平路校区)校园水及自来水进行加标回收实验,分别添加1μM、3μM、4μM和7μM的金霉素,利用上述方法进行测试,得到的金霉素回收率为97.25%-101.67%,具体结果如附表1所示。3) Detection of aureomycin in water samples: take 0.5mL pretreated water sample, mix with 0.5mL fluorescent probe solution to obtain a mixed sample, use 365nm ultraviolet lamp as excitation light source to obtain fluorescence image and use image analysis software to obtain image B/G, and then according to the fitting equation, the corresponding concentration of aureomycin was obtained. The campus water and tap water of Tongji University (Siping Road Campus) were collected for standard recovery experiments, adding 1 μM, 3 μM, 4 μM and 7 μM aureomycin respectively, and using the above method to test, the recovery rate of aureomycin was 97.25%-101.67 %, the specific results are shown in Attached Table 1.
表1加标回收实验结果Table 1 The results of the standard recovery experiment
实施例5:Example 5:
以实施例1合成的基于环糊精-组氨酸作为荧光探针,对不同共存或结构相似的小分子有机物进行选择性检测,具体方法如下:Using the cyclodextrin-histidine synthesized in Example 1 as a fluorescent probe to selectively detect different coexisting or structurally similar small molecular organic compounds, the specific method is as follows:
将基于环糊精-氨基酸荧光分子分散至去离子水中,浓度为200μM,用作荧光探针;同时配置多份200μM的不同小分子有机物溶液分别包括金霉素(CTC)、乙酸(AC)葡萄糖(Glucose)、氨苄青霉素(Amp)、氯霉素(CAP)、链霉素(Str)、萘啶酸(Nal)、甘氨酸(Gly)、组氨酸(His)、苯丙氨酸(Phe)、色氨酸(Trp)、三氯乙酰胺(TCAM)、四环素(TC)、土霉素(OTC)、美诺环素(MOC)、并各取1mL与等体积的荧光探针溶液混合,静置待反应体系稳定后,测试其荧光光谱(以365nm紫外灯为激发光源),考察其选择性识别能力,如图6所示,加入金霉素后,体系的荧光信号明显增强,同时发射峰蓝移,而其它小分子有机物加入后体系的荧光响应没有明显变化,表明该方法具有良好的选择性,实现了环糊精-组氨酸荧光探针对金霉素的特异性识别。Disperse fluorescent molecules based on cyclodextrin-amino acids in deionized water at a concentration of 200 μM, and use them as fluorescent probes; at the same time, prepare multiple 200 μM solutions of different small molecule organic substances, including aureomycin (CTC), acetic acid (AC) and glucose (Glucose), ampicillin (Amp), chloramphenicol (CAP), streptomycin (Str), nalidixic acid (Nal), glycine (Gly), histidine (His), phenylalanine (Phe) , tryptophan (Trp), trichloroacetamide (TCAM), tetracycline (TC), oxytetracycline (OTC), minocycline (MOC), and
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。The above descriptions of the embodiments are for those of ordinary skill in the art to understand and use the invention. It is obvious that those skilled in the art can easily make various modifications to these embodiments, and apply the general principles described here to other embodiments without creative effort. Therefore, the present invention is not limited to the above-mentioned embodiments. Improvements and modifications made by those skilled in the art according to the disclosure of the present invention without departing from the scope of the present invention should fall within the protection scope of the present invention.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210966480.1A CN115340615B (en) | 2022-08-12 | 2022-08-12 | Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210966480.1A CN115340615B (en) | 2022-08-12 | 2022-08-12 | Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115340615A CN115340615A (en) | 2022-11-15 |
| CN115340615B true CN115340615B (en) | 2023-05-02 |
Family
ID=83951856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210966480.1A Active CN115340615B (en) | 2022-08-12 | 2022-08-12 | Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115340615B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117126307B (en) * | 2023-08-09 | 2025-07-22 | 同济大学 | Preparation method and application of cyclodextrin-histidine/lanthanum-based complex |
| CN118908430B (en) * | 2024-10-10 | 2024-12-10 | 甘肃泰升化工科技有限公司 | An online anti-scaling and descaling agent for circulating water and a preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103052387A (en) * | 2010-07-22 | 2013-04-17 | 德国麦氏大药厂 | Pharmaceutical composition containing a tryptophan derivative |
| CN104383554A (en) * | 2002-09-06 | 2015-03-04 | 天蓝制药公司 | Cyclodextrin-based polymers for therapeutics delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US20050153913A1 (en) * | 2001-04-10 | 2005-07-14 | Kosak Kenneth M. | Nucleic acid carrier compositions and methods for their synthesis |
| US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| CA2618878C (en) * | 2005-08-18 | 2016-06-28 | Ambrx, Inc. | Compositions of trna and uses thereof |
| NZ568578A (en) * | 2005-12-14 | 2011-10-28 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| US8569463B2 (en) * | 2009-04-23 | 2013-10-29 | Syracuse University | Method of covalently modifying proteins with organic molecules to prevent aggregation |
| CN108568278A (en) * | 2017-03-13 | 2018-09-25 | 广州市芯检康生物科技有限公司 | A kind of novel instant aerogel microball and preparation method thereof |
| JP7565588B2 (en) * | 2018-03-06 | 2024-10-11 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods relating thereto |
| CN109232589B (en) * | 2018-10-19 | 2021-04-06 | 贵州大学 | A kind of fluorescent probe and its preparation and application |
| CN111875717B (en) * | 2020-07-13 | 2022-05-10 | 盐城师范学院 | Cyclodextrin-type fluorescent probe and preparation method and application thereof |
-
2022
- 2022-08-12 CN CN202210966480.1A patent/CN115340615B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383554A (en) * | 2002-09-06 | 2015-03-04 | 天蓝制药公司 | Cyclodextrin-based polymers for therapeutics delivery |
| CN103052387A (en) * | 2010-07-22 | 2013-04-17 | 德国麦氏大药厂 | Pharmaceutical composition containing a tryptophan derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115340615A (en) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115340615B (en) | Fluorescent molecule based on cyclodextrin-amino acid and synthetic method and application thereof | |
| Song et al. | Ratiometric fluorescence detection of trace water in organic solvents based on aggregation-induced emission enhanced Cu nanoclusters | |
| CN110982521B (en) | Graphite phase carbon nitride quantum dot composite and its synthesis method and biological application | |
| CN108489951A (en) | Double fluorescent emission copper nano-cluster/carbon dots colorimetric probes, preparation method and the application in trace water context of detection | |
| CN104449674B (en) | Chitosan rod-like microcrystalline fluorescent probe, preparation method and trace metal ion detecting method | |
| Wang et al. | UiO-66-NH 2 based fluorescent sensing for detection of tetracyclines in milk | |
| CN106970061A (en) | The preparation method of carbon point/copper nano-cluster compound ratio fluorescent dopamine probe | |
| CN107014787B (en) | Application of glutathione template gold nanocluster in detection of cysteine and lysine | |
| Sun et al. | 2, 4-Dinitrobenzenesulfonate-functionalized carbon dots as a turn-on fluorescent probe for imaging of biothiols in living cells | |
| CN115960603B (en) | A fluorescent sulfur quantum dot and its synthesis method and application | |
| CN111363542B (en) | Full-color fluorescent CaF 2 And use of CaF 2 Prepared furfural molecular imprinting ratio fluorescence sensor and preparation method thereof | |
| CN108276383A (en) | A kind of fluorescence probe and preparation method thereof of identification iodide ion and recognition methods | |
| CN115975636B (en) | Chiral carbon dot, preparation method and application thereof | |
| CN109825284B (en) | Ethylenediamine-beta-cyclodextrin modified Mn doped ZnS quantum dot and preparation method and application thereof | |
| CN107739394B (en) | A kind of Supramolecular self assembly body and the preparation method and application thereof for copper ion fluoroscopic examination | |
| CN112898969B (en) | Application of fluorescent carbon dots in the fields of illumination, ion detection and temperature sensing | |
| CN115010833A (en) | A Fluorescent Polymer Responsive to Acid-Base Stimuli and Its Application in Optical Encryption | |
| CN112300335B (en) | Preparation method and application of molecular imprinting sensor based on F-PDA (Fabry-Perot digital Assistant) | |
| CN103242828B (en) | Method for adjusting fluorescence performance of conjugate polyelectrolyte | |
| CN111115693B (en) | A kind of preparation method and application of multicolor fluorescent FeS2 quantum dot | |
| CN118320807A (en) | Magnesium-doped fluorescent carbon dot nano enzyme and preparation method and application thereof | |
| CN110257055B (en) | Ratio-type fluorescent probe for highly selective detection of glutathione, synthesis method and application | |
| CN110006869B (en) | Zein-based gold nanocluster fluorescent probe and preparation method of test paper | |
| Witz et al. | Hydrophobic fluorescence probe studies with poly-L-lysine | |
| CN107966425B (en) | A ratiometric fluorescent probe of morpholinoguanidine based on copper nanocluster/fluorescein complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |